14 Results for "

MSU

" in MedChemExpress (MCE) Product Catalog:
Products (14)

14 Results for "MSU" in MCE Product Catalog:

22
22 Publications Verification
Cat. No.: HY-B2130A
CAS No.: 1198-77-2
Synonyms: Monosodium urate
Uric acid sodium (Monosodium urate), scavenger of oxygen radical, is a very important antioxidant that help maintains the stability of blood pressure and antioxidant stress. Uric acid sodium can remove reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, inhibiting lipid peroxidation .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-126382
CAS No.: 24292-52-2
Purity:  ≥98.0%
Hesperidin methylchalcone (Hesperidin methyl chalcone) is an orally active flavonoid that has analgesic, anti-inflammatory and antioxidant properties. Hesperidin methylchalcone exhibits vasoprotective activity. Hesperidin methylchalcone inhibits oxidative stress, cytokine production and NF-κB activation. Hesperidin methylchalcone can be used for the research of gout disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-100712
CAS No.: 43077-30-1
Purity:  98.39%
DPO-1 is a potent Kv1.5 and Kv1.3 (EC50 = 3.1 μM) channels inhibitor with potential immunomodulatory and anti-inflammatory effects. DPO-1 reduces Kv1.3 current density, blunts Ca 2+ influx in Ca 2+-depleted Jurkat cells, and inhibits IL-2 secretion in activated Jurkat cells. DPO-1 inhibits Uric acid sodium (HY-B2130A) (MSU)-induced NLRP3 inflammasome activation by blocking Kv1.5-mediated K + efflux. DPO-1 can be used for the study of immunologic disorders and atrial fibrillation .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-163358
SLC3037 is a NLRP3 inhibitor which blocks NLRP3 from binding to NEK7 or oligomerization, inhibiting inflammasome caused by MSU and other inflammasome activators. SLC3037 can be used for research of gout, cardiovascular diseases, metabolic syndrome or neurodegenerative diseases .
loading...
    loading...
Cat. No.: HY-153873
CAS No.: 1629160-83-3
Purity:  99.52%
Research Areas:  

Cancer

MSU38225 is a selective Nrf2 inhibitor. MSU38225 increases ROS levels by inhibiting antioxidant production. MSU38225 arrests cells at the G2/M phase, enhances cellular sensitivity to chemotherapeutic agents, and exerts synergistic effects with Carboplatin (HY-17393) and 5-fluorouracil (HY-90006). MSU38225 exhibits anticancer activity against lung cancer. MSU38225 can be used in research related to non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-153832
CAS No.: 2456434-36-7
Purity:  98.43%
Target:  

RAR/RXR NO Synthase

Research Areas:  

Cancer

MSU-42011 is an orally active retinoid X receptor (RXR) agonist. MSU-42011 inhibits the iNOS activity and reduces the expression of p-ERK protein. MSU-42011 has immunomodulatory and antitumor activity .
loading...
    loading...
Cat. No.: HY-163181
CAS No.: 2810846-51-4
Target:  

Bacterial

Research Areas:  

Infection

MSU-43085 is an orally active MmpL3 inhibitor of Mycobacterium tuberculosis (Mtb). MSU-43085 effectively inhibits Mtb in an acute murine tuberculosis infection model. MSU-43085 can be used in tuberculosis research .
loading...
    loading...
Cat. No.: HY-RS01409
Research Areas:  

Others

BCKDHA Human Pre-designed siRNA Set A contains three designed siRNAs for BCKDHA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-181283
CAS No.: 2919699-59-3
Target:  

Bacterial

Research Areas:  

Infection

MSU-43557 is a Mycobacterium abscessus MmpL3 (MAB_4508) inhibitor and bactericidal agent. MSU-43557 inhibits MmpL3 function, disrupts trehalose monomycolate synthesis, and reduces biofilm-associated Mycobacterium abscessus viability. MSU-43557 exerts bactericidal activity against intracellular Mycobacterium abscessus. MSU-43557 shows low eukaryotic cytotoxicity and low Mycobacterium abscessus resistance frequency. MSU-43557 can be used for the research of mycobacterium abscessus infection .
loading...
    loading...
Cat. No.: HY-162846
CAS No.: 3040298-34-5
Research Areas:  

Inflammation/Immunology

NLRP3-IN-44 (compound P33) is a potent and orally active (approximately 62%) inhibitor of NLRP3, with the Kd of 17.5 nM. NLRP3-IN-44 plays an important for studying NLRP3 inflammasome-mediated diseases .
loading...
    loading...
Cat. No.: HY-181282
CAS No.: 3105177-29-2
Target:  

Bacterial

Research Areas:  

Infection

MSU-44147 is an inhibitor and antimicrobial agent targeting MmpL3 in Mycobacterium abscessus, with low eukaryotic cytotoxicity, a narrow antimicrobial spectrum that is specific only to mycobacteria, and low drug resistance frequency. MSU-44147 reduces trehalose dimycolate levels by inhibiting MmpL3 function, disrupts biofilm formation and reduces the viability of related bacteria, while exerting bactericidal effects on intracellular Mycobacterium abscessus. MSU-44147 exhibits additive or synergistic effects with antibiotics and can be used in research on multidrug-resistant isolates and infections of Mycobacterium abscessus .
loading...
    loading...
Cat. No.: HY-181488
CAS No.: 3097745-69-9
NLRP3-IN-87 is a selective and orally active NLRP3 inhibitor with a Kd of 0.23 μM. NLRP3-IN-87 binds directly to the NLRP3 NACHT domain, disrupts NLRP3-NEK7 and NLRP3-ASC interactions, inhibits ASC oligomerization, and blocks inflammasome assembly. NLRP3-IN-87 suppresses caspase-1 activation and IL-1β secretion. NLRP3-IN-87 exhibits anti-inflammatory and analgesic activity, reducing joint swelling, inflammation, and pain in an MSU (HY-B2130A)-induced acute gout mouse model. NLRP3-IN-87 can be used for the research of gout .
loading...
    loading...
Cat. No.: HY-100712R
CAS No.: 43077-30-1
DPO-1 (Standard) is the analytical standard of DPO-1 (HY-100712). This product is intended for research and analytical applications. DPO-1 is a potent Kv1.5 and Kv1.3 (EC50 = 3.1 μM) channels inhibitor with potential immunomodulatory and anti-inflammatory effects. DPO-1 reduces Kv1.3 current density, blunts Ca2+ influx in Ca2+-depleted Jurkat cells, and inhibits IL-2 secretion in activated Jurkat cells. DPO-1 inhibits Uric acid sodium (HY-B2130A) (MSU)-induced NLRP3 inflammasome activation by blocking Kv1.5-mediated K+ efflux. DPO-1 can be used for the study of immunologic disorders and atrial fibrillation .
loading...
    loading...
Cat. No.: HY-182380
CAS No.: 1632152-27-2
ODZ10117 is a STAT3 and NLRP3 inhibitor with a human STAT3 SH2 domain IC50 of 7.5 μM. ODZ10117 binds to the STAT3 SH2 domain, suppressing tyrosine phosphorylation, dimerization, nuclear translocation, and transcriptional activity. ODZ10117 binds to NLRP3, impairs NEK7 interaction, prevents inflammasome formation, and inhibits caspase-1 and IL-1β cleavage.ODZ10117 reduces MSU (HY-B2130A)-induced IL-1β release, lowers LPS (HY-D1056)-induced sepsis mortality, and exhibits anti-inflammatory effects. ODZ10117 induces apoptosis, suppresses breast cancer cell migration and invasion, reduces tumor growth and lung metastasis, and extends survival in breast cancer models. ODZ10117 can be used for the research of Monosodium urate (HY-B2130A)-induced peritonitis, LPS-induced sepsis, breast cancer, glioblastoma, and Alzheimer's disease .
loading...
    loading...
  • 1